Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction

Expert Review of Anticancer Therapy

Volumn 8, Issue 12, 2008, Pages 1953-1964

  Ku, Geoffrey Y ^a   Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemoradiation; Chemoradiotheraphy; Chemotherapy; Combined modality therapy; Esophageal cancer; Neoadjuvant

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CALDESMON; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; THYMIDYLATE SYNTHASE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RADIATION DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; ESOPHAGUS TUMOR; PATHOLOGY;

COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS;

EID: 61449375546     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.12.1953     Document Type: Review

References (92)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
3. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. 31(4), 450-464 (2004).
4. Devesa SS, Fraumeni JF Jr. The rising incidence of gastric cardia cancer. J. Natl Cancer Inst. 91(9), 747-749 (1999).
5. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br. J. Surg. 77(8), 845-857 (1990).
6. Hulscher JB, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N. Fngl. J. Med. 347(21), 1662-16619 (2002).
7. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br. J. Surg. 67(6), 381-390 (1980).
8. Enzinger PC, Mayer RJ. Esophageal cancer. N. Engl. J. Med. 349(23), 2241-2252 (2003).
9. Harris DT, Mastrangelo MJ. Theory and application of early-systemic therapy. Semin. Oncol. 18(6), 493-503 (1991).
10. Kok T, Lanschot J, Siersema P, Overhagen H, Tilanus H. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a Phase III multicenter randomized controlled trial. Presented at: American Society of Clinical Oncology Annual Meeting CO, USA 17-20 May (1997).
11. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 339(27), 1979-1984 (1998).
12. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (9319), 1727-1733 (2002).
13. Allum W, Fogarty P, Stenning S, Langley R; NUGCCS Group. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable: esophageal cancer. Presented at: Gastrointestinal Cancers Symposium Orlando, FL, USA, 25-28 January 2008.
14. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8(3), 226-234 (2007).
15. Thirion P, Michiels S, Le Maitre A, Tierney J, Group MoCiECC. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 4512).
16. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
17. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 4510).
18. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann. Surg. Oncol. 10(7), 754-761 (2003).
19. Maltharier RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst. Rev. 3, CD001556 (2006).
20. Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2(1), 35 (2004).
21. Kelsen DP, Minsky B, Smith M et al. Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J. Clin. Oncol. 8(8), 1352-1361 (1990).
22. Arnott SJ, Duncan W, Kerr GR et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother. Oncol. 24(2), 108-113 (1992).
23. Nygaard K, Hagen S, Hansen HS et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, Multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J. Surg. 16(6), 1104-1109 (1992).
24. Arnott SJ, Duncan W, Gignoux M et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst. Rev. 4, CD001799 (2005).
25. Coia LR, Engstrom PF, Paul AR, Stafford PM, Hanks GE. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 20(1), 29-36 (1991).
26. Valerdi JJ, Tejedor M, Illarramendi JJ et al. Neoadjuvant chemotherapy and radiotherapy in locally advanced esophagus carcinoma: long-term results. Int. J. Radiat. Oncol. Biol. Phys. 27(4), 843-847 (1993).
27. Berger AC, Farina J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J. Clin. Oncol. 23 (19), 4330-4337 (2005).
28. Makary MA, Kiernan PD, Sheridan MJ et al. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy. Am. Surg. 69(8), 693-700 (2003).
29. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J. Clin. Oncol. 23(10) 2310-2317 (2005).
30. Heath EI, Burtness BA, Heitmiller RF et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J. Clin. Oncol. 18(4), 868-876 (2000).
31. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J. Clin. Oncol. 11(6), 1118-1123 (1993).
32. Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur. J. Cancer 38(2), 300-313 (2002).
33. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus; N. Engl. J. Med. 326(24), 1593-1598 (1992).
34. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281(17), 1623-1627 (1999).
35. Minsky BD, Neuberg D, Kelsen DP et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int. J. Radiat. Oncol. Biol. Phys. 43(3), 517-523 (1999).
36. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J. Clin. Oncol. 20(5), 1167-1174 (2002).
37. Gaspar LE, Winter K, Kocha WI et al. A Phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 88 (5), 988-995, (2000).
38. Urba SG, Orringer MB, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 19(2), 305-313 (2001).
39. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335 (7), 462-467 (1996).
40. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann. Surg. 230(3), 392-400 (1999).
41. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N. Engl. J. Med. 337(3), 161-167 (1997).
42. Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled Phase III trial. Lancet Oncol. 6(9), 659-668 (2005).
43. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase Ill trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J. Clin. Oncol. 26(7), 1086-1092 (2008).
44. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 137(2), 172-177 (2005).
45. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53(7), 925-930 (2004).
46. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 185 (6), 538-543 (2003).
47. Stahl M, Walz M, Stuschke M et al. Preoperativc chemotherapy (CTX) versus preoperative chemoraradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: first results of a randomized Phase III trial. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 4511).
48. Stahl M, Wilke H, Lehmann N, Stuschke M, Group; GOCS. Long-term results of a Phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 4530).
49. Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J. Clin. Oncol. 25(10), 1160-1168 (2007).
50. Jouve J, Michel P, Mariette C et al. Outcome of the nonrandomized patients in the FFCD 9102 trial: chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. Presented at: American Society of Clinical Oncology. Chicago, IL, 30 May-3 June 2008 (Abstract 4555).
51. Carstens H, Albertsson M, Friesland S et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 4530).
52. Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac. Cardiovasc. Surg. 114(2), 205-209 (1997).
53. Ando N, Iizuka T, Ide H et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J. Clin. Oncol. 21(24), 4592-4596 (2003).
54. Igaki H, Kato H, Ando N et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 4510).
55. Pouliquen X, Leyard H, Hay JM et al. 5-floorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research, Ann. Surg.. 223(2), 127-133 (1996).
56. Armanios M, Xu R, Forastiere AA et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: Phase II trial (E8296) of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(22), 4495-4499 (2004).
57. Teniere P, Hay JM, Fingerhat A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg. Gynecol. Obstet. 173(2), 123-130 (1991).
58. Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 113(2), 138-147 (1993).
59. Xiao ZF, Yang ZY, Liang J et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann. Thorac. Surg. 75(2), 331-336 (2003).
60. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
61. Adelstein DJ, Rice TW, Rybicki LA et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J. Clin. Oncol. 18(10), 2032-2039 (2000).
62. Blanke CD, Choy H, Teng M et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin. Radiat. Oncol. 9(2, Suppl. 1), 43-52 (1999).
63. Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98(10), 2177-2183 (2003).
64. Brenner B, Ilson DH, Minsky BD et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J. Clin. Oncol. 22(1), 45-52 (2004).
65. Safran H, Gaissert H, Akerman P et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest. 19(1), 1-7 (2001).
66. van Meerten E, Muller K, Tilanus HW et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a Phase II study. Br. J. Cancer 94(10), 1389-1394 (2006).
67. Henry LR, Goldberg M, Scott W et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a Phase II report. Ann. Surg. Oncol. 13(2), 214-220 (2006).
68. Meluch AA, Greco FA, Gray JR et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network Phase II trial. Cancer J. 9(4), 251-260 (2003).
69. Weiner LM, Colarusso P, Goldberg M, Dresler C, Coia LR. Combined-modality therapy for esophageal cancer: Phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin. Oncol. 24(6 Suppl. 19), S19-93-S19-95 (1997).
70. Wright CD, Wain JC, Lynch TJ et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a Phase I and II study. J. Thorac. Cardiovasc. Surg. 114(5), 811-815 (1997).
71. Roof KS, Coen J, Lynch TJ et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 65(4), 1120-1128 (2006).
72. Schuller J, Balmer-Majno S, Mingrone W et al. Preoperative induction chemotherapy with docetaxel-cisplatin followed by concurrent docetaxel-cisplatin and radiation therapy (RT) in patients with locally advanced esophageal cancer: final results of the multicenter Phase II trial SAKK 75/02. Presented at: American Sociery of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 4550).
73. Hihara J, Yoshida K, Hamai Y et al. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res. 27(4C), 2597-2603 (2007).
74. Higuchi K, Koizumi W, Tanabe S et al. A Phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato Digestive Disease and Oncology Group trial (KDOG 0501). Radiother. Oncol. (2008).
75. O'Connor BM, Chadha MK, Pande A et al. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J. 13(2), 119-124 (2007).
76. Khushalani NI, Leichman CG, Proulx G et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J. Clin. Oncol. 20(12), 2844-2850 (2002).
77. Enzinger P, Mamon H, Choi N et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 22-24 January 2004 (Abstract 35).
78. Ilson DH, Bains M, Kelsen DP et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J. Clin. Oncol. 21(15), 2926-2932 (2003).
79. Ku G, Bains M, Rizk N et al. Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007 (Abstract 9).
80. Kleinberg L, Powell M, Forastiere A et al. E1201: an Eastern Cooperative Oncology Group (ECOG) randomized Phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/ RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007 (Abstract 4533).
81. Kleinberg L, Powell M, Forastiere A et al. Survival outcome of E1201: an Eastern Cooperative Oncology Group (ECOG) randomized Phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 4532).
82. Gonen M, Hummer A, Zervoudakis A et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J. Clin. Oncol. 21(3), 406-412 (2003).
83. Kubota T, Watanabe M, Otani Y, Kitajima M, Fukushiuma M. Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res. 22(6B), 3537-3540 (2002).
84. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006).
85. Kamoshida S, Suzuki M, Shimomura R et al. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/ cisplatin in gastric cancer. Br. J. Cancer. 96(2), 277-283 (2007).
86. Langer R, Specht K, Becker K et al. Association of pretherapeutic expression of chemotherapy-retated genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin. Cancer Res. 11(20), 7462-7469 (2005).
87. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J. Clin. Oncol. 21(3), 428-432 (2003).
88. Flamen P, Van Cutsem F, Lerut A et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann. Oncol. 13(3), 361-368 (2002).
89. Ott K, Weber WA, Lordick F et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J. Clin. Oncol. 24(29), 4692-4698 (2006).
90. Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 19(12), 3058-3065 (2001).
91. Lordick F. Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON Phase II trial. Lancet Oncol. 8(9), 797-805 (2007).
92. Lordick F, Ott K, Krause B et al. Salvage radiochemotherapy in locally advanced gastroesophageal junction tumors that are metabolically resistant to induction chemotherapy: the MUNICON-2 trial. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25-27 January 2008 (Abstract 104).